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Purpose: To quantify the ability of correlation and regression analysis to extract the normal lung dose-response function from dose vol-
ume histogram (DVH) and radiation pneumonitis (RP) data. 
Methods: A local injury model is adopted, in which radiation-induced damage (functional loss) G is the integral of the DVH with function 
R(D).  RP risk is H(G) where H() is the sigmoid cumulative distribution of functional reserve.  RP incidence is a Bernoulli function of risk. 
A homogeneous patient cohort is assumed, allowing non-dose-related factors to be ignored. Clinically realistic DVHs are combined with 
the injury model to simulate RP data. 
Results: Correlation analysis is often used to identify a subset of predictor variables that are significantly correlated with outcome, for 
inclusion in a predictive model. In the local injury model, all DVH metrics VD contribute to damage through the integral with R(D).  
Correlation analysis therefore has limited value. The subset of VD that are most significantly correlated with incidence varies randomly 
from trial to trial as a result of random variations in the DVH set, and does not necessarily reveal anything useful about the patient cohort 
or the underlying biological dose-response relationship. Regression or matrix analysis has the potential to extract R(D) from damage or 
risk data, provided smoothness regularization is employed. Extraction of R(D) from incidence data was not successful, due to its higher 
level of statistical variability. 
Conclusions: To the authors’ knowledge, smoothness regularization has not been applied to this problem, so represents a novel approach. 
Dose-response functions can be successfully extracted from measurements of integral (as opposed to regional) lung damage G, suggesting 
value in re-visiting available measurements of ventilation, perfusion and radiographic damage. The techniques developed here can poten-
tially be used to extract the dose-response functions of different tissues from multiple types of quantitative volumetric imaging data. 
This manuscript will be submitted to a journal.  
I. INTRODUCTION  
Forward progress in radiation therapy (RT) depends on 
the ability to establish rigorous causal relationships between 
patient characteristics and treatment parameters on the one 
hand, and treatment outcomes on the other. Patient charac-
teristics include comorbidities, performance status, genetic 
markers, etc. Treatment parameters include first and fore-
most the planned 3D dose distribution, but also fractiona-
tion, concurrent chemotherapy, immobilization and motion 
management. Outcomes include overall survival, local tu-
mor control, and a variety of site-specific toxicities and 
complications that potentially degrade patients’ quality of 
life.  
A key pitfall is to attribute clinical significance to results 
that are in fact incidental artifacts of either the specific da-
taset, or the analysis technique. This work uses radiation 
pneumonitis (RP), one of the principal complications of 
lung cancer RT, to illustrate the challenges of extracting 
dose-response relationships from clinical dose-volume his-
togram (DVH) data. 1 A local damage / injury model similar 
to Jackson et al 2 is adopted. It is assumed that normal lung 
is a parallel organ, and that radiation-induced loss of func-
tion can be modeled using a biological dose-response pro-
file P(D), which gives the probability of sub-volume dam-
age as a function of local dose D.  
Integral damage G is the integral of the differential DVH 
with P(D), or of the cumulative DVH with R(D) ≡ P′(D). 
RP risk (or jeopardy) J  is assumed to be a sigmoid function 
of G, modeled for example using the Lyman-Kutcher-
Burman equations. 3 RP incidence I is a binary variable 
indicating whether RP above some threshold was (was not) 
experienced. I is distributed according to the Bernoulli dis-
tribution B(J)  (i.e., binomial distribution for a single trial 
having probability of success J). For the purposes of this 
study, non-dose-related factors are ignored  —  damage G, 
and therefore risk J and incidence I, are assumed to depend 
solely on the DVH. For the extraction of dose-response 
relationships, this represents a best-case scenario. Clinical 
RP data is likely to reflect a range of non-dose factors, and 
will therefore be more challenging.  
DVHs from the University of Michigan (UM) dose esca-
lation trial reported by Kong 4 are used to generate multiple 
random sets of clinically realistic lung DVHs, simulating 
the results of multiple clinical trials. The DVHs are com-
bined with two hypothetical dose-response profiles P(D) to 
obtain simulated RP data.  Correlation and regression analy-
sis is then applied to the simulated RP data to see how well 
different analytical techniques can recover the known dose-
response profile. Specifically, damage is approximated as a 
weighted sum over dose metrics VDi, where VDi is the 
volume of normal lung receiving dose of Di or greater, cal-
culated at doses Di = 5, 10, 15, ... , 100 Gy. Statistical anal-
ysis attempts to recover the weights multiplying VDi.  
We find that correlation analysis provides little useful in-
formation regarding the underlying dose-response. The set 
of VDi that are most significantly correlated with RP varies 
randomly between trials, and is unrelated to the contribution 
of  VDi to damage G.  No significance can be read into the 
fact that, e.g., V5 or V13 is significantly correlated with RP 
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in some trials, but not in others. Regression analysis is able 
to extract P(D) from damage or risk data, but not from inci-
dence data. The statistical variability inherent in incidence 
data challenges the regression algorithms. In order to suc-
cessfully extract P(D) from damage or risk data, appropriate 
regularization (smoothness penalties) must be employed.  
Conventional L1 and L2 regularization are ineffective.  
In summary, to have a good prospect of extracting P(D) 
from DVH data, surrogate measurements of damage G 
should be incorporated into clinical trials. In the case of 
normal lung, candidate surrogates include perfusion and 
diffusion loss, and radiographic damage. This work em-
ploys a novel smoothness regularization technique that has 
not previously been applied to this problem. Without this 
technique, regression analysis returns noisy results, due to 
the mathematically ill-posed nature of the regression prob-
lem. Provided accurate estimates of integral damage are 
available, the techniques developed here can reliably recov-
er the dose-response functions P(D) and R(D) from DVH 
and damage data. Extracting the dose-response function 
from incidence data is more challenging.  
II. MATERIALS AND METHODS 
A. University of Michigan DVH Data 
UM data is reported in detail by Kong 4 (see also prior 
publications cited by Kong), and has been previously ana-
lyzed in Gordon et al. 5,6   In summary, the UM dataset con-
sists of 89 DVHs for total lung minus gross tumor volume 
(GTV). Treatments were either RT alone or RT with neoad-
juvant chemotherapy. RT planning employed 3D conformal 
RT (3DCRT). Patients received daily fractions of 2.1 Gy, 
with total dose escalated from 63 Gy based on normal tissue 
tolerance. Grading of RP was according to SWOG 
(www.swog.org) rules, with clarifications noted in Kong. 
Data were provided in anonymized form for patients who 
had known RP status at a time point 6 months after the start 
of treatment. RP grading was as follows (G = grade): G0: 
42, G1: 30, G2: 12, G3: 5, G4+: 0. DVHs were given as 
absolute lung volumes (in cubic centimeters (cc)) in dose 
bins with centers from 0.5 Gy to 119.5 Gy in steps of 1 Gy, 
calculated using the UMPlan treatment planning system. 
DVH dose values were provided as 2 Gy equivalent 
(EQD2) based on an α/β ratio of 2.5 Gy. The present study 
converted EQD2 doses to physical doses before integrating 
with damage profiles.  
Figure 1 shows a plot of mean lung dose (MLD) versus 
DVH number for the University of Michigan dataset. Actual 
radiation pneumonitis (RP) incidence, derived from the 
clinical trial, is indicated by symbol. Pink solid triangles are 
grade 3 DVHs. Red solid circles are grade 2 DVHs. Blue 
hollow diamonds are grade 1 DVHs. Gray hollow squares 
are grade 0 DVHs. Note that these toxicity gradings are 
ignored in the simulated trials, to be described below. In the 
simulations, damage, risk and incidence values are generat-
ed using the equations given in sections 2.2 – 2.4. The gray 
band indicates DVHs having 15 Gy ≤ MLD ≤ 20 Gy. 
DVHs from this MLD range are used to illustrate differ-
ences in correlation behavior between DVH subsets and the 
full DVH set. 
B. Simulated DVHs 
To simulate a clinical trial, some number N (e.g., N = 
100) of simulated  DVHs are generated from the UM 
DVHs, either from the full set, or from the subset having 15 
Gy ≤ MLD ≤ 20 Gy. To generate each simulated DVH 
(DVHsim), two randomly selected UM DVHs (DVHUM1 
and DVHUM2) are combined with a uniformly-distributed 
random weight:  
 	 =  ∙ 	 + 1 − 	 ∙ 	 (1) 
 
where µ ∈ [0,1] is the weight. By default all simulated 
DVHs are assumed to be associated with conventional 30-
fraction treatment courses. However, results are not ex-
pected to depend on the assumed fractionation, and will 
apply more generally to other fractionation schemes. 
C. NTCP Model 
In the following DVH(D) and cDVH(D) denote differen-
tial and cumulative DVHs: 	 = /			, 	 = 	 	 . This work adopts a local damage 
/ injury model similar to Jackson et al. 2 (See also Niemier-
ko 7 and Rutkowska. 8) It is assumed that lung is a parallel 
organ, and that radiation-induced loss of function (damage) 
can be modeled using a probability profile P(D), which 
gives the probability of sub-volume damage as a function of 
local dose D. Integral damage G is obtained by integrating 
DVH(D) ·  P(D). Mathematically this is equivalent to inte-
grating cDVH(D) ·  R(D), where R(D) is the derivative of 
P(D):  R(D) = /	 P(D) ≡ P′(D). For this work, func-
tions P(D) are referred to as damage profiles, and functions 
R(D) are referred to as rate profiles.  
  =  	 ∙ 	 	 
 =  	 ∙ 		  (2) 
 
Radiation pneumonitis is assumed to occur when G ex-
ceeds the lungs’ functional reserve. As in Jackson et al 2, RP  
risk or jeopardy, denoted  by J, is given by J = H(G), where 
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H(G) is the cumulative distribution of functional reserves in 
the patient population. Based on clinical  data, H(G) is a 
sigmoid function, modeled e.g., using the LKB equation 3 
 	 = 		 	≈ 		 !"#, 	%& , 	 (3) 
 
where G50 is the damage value corresponding to 50% risk 
of RP, and mG is the LKB slope parameter. For a specific 
patient, incidence I is a binary random variable taking the 
value 0 (RP absent) with probability (1 − J), or the value 1 
(RP present) with probability J    
 '		~		"	 (4) 
 
where  B(p)  is the Bernoulli distribution (i.e., binomial 
distribution for a single trial having probability of success 
p).  Equivalently, I is 0 if the patient’s functional reserve is 
greater than or equal to G, 1 if it is less than G. For his work 
we further define “RP” to mean clinically diagnosed RP of 
grade 2 or higher (G2+) according to SWOG criteria. I = 0 
(or 1) therefore signifies G1–  (or G2+)  RP. However, 
results are not dependent on this definition, and will apply 
also to alternative RP definitions. 
D. Simulated RP Data 
Simulated damage values G are calculated from the 
DVHs in section 2.2 by combining them with hypothetical 
damage profiles P(D) (or R(D)). This work considers two 
types of damage profile: linear quadratic (LQ) 3 profiles 
having the form  
 
 	 = 	1 − exp	−, + -/.	)  (5) 
 
and Joiner’s induced repair model (IRM) 9 which modi-
fies the LQ model by adding an initial low-dose section 
with steeper slope, followed by a section with shallower 
slope, before asymptoting to LQ behavior. The original 
IRM equations model single-fraction cell survival curves, 
but may be generalized to multiple fractions by assuming 
that, similar to LQ curves, the N-fraction cell survival curve 
SN(D)  is given by SN(D) = S1(D/N)N, where S1(D) is the 
single-fraction survival curve. The generalized IRM equa-
tions for the damage profile P(D)  = 1 ─  SN(D)  are: 
 	 = 	1 − exp	−[,/.	 + -/.]) (6) ,	 = 	,1 − ,1 − ,	 ∙ exp	−/2	) (7) 
 
where, as in Joiner’s original formulation,  αs is the ini-
tial slope and αr is the final slope of the single-fraction cell 
survival curve, Dc is a critical dose that determines the tran-
sition from αs to αr, and β is the usual LQ parameter.  
This work adopts the following LQ model parameters:  α 
= 0.01 Gy-1, β = 0.005 Gy-2 and α/β = 2 Gy. The α value is 
derived from the in-vivo SPECT perfusion loss measure-
ments reported by Koontz et al. 10 Recent measurements  
10,11
 suggest that the α/β ratio for normal lung is lower than 
3 Gy, motivating the value α/β = 2 Gy. Based on Gordon et 
al. 5  selected IRM model parameters are αs = 0.04,  αr = 
0.0032, Dc = 0.22, β = 0.0032, and αr/β = 1. The default 
assumption in this work is that the number of fractions N = 
30. Figure 2 plots P(D) and R(D) for LQ and IRM profiles 
having  N = 30 and the above parameter values.  
Damage values are translated into risk values using the 
LKB model (equation (3)). For LQ profiles we assume G50 
= 0.27 and mG = 0.25. For IRM profiles we assume G50 = 
0.18 and mG = 0.25. (Note that a G50 value of 0.27 (0.18) 
implies that RP risk is 50% when 27% (18%) of normal 
lung is damaged.) For conventionally fractionated  RT,  
Borst et al 12 report crude incidence rates of RP to be 17.6%. 
The LKB parameters are selected to give RP incidence of 
around 17%, consistent with the clinical values reported by 
Borst.  
The LQ model is a generally accepted model of radia-
tion-induced cell damage.  Motivation for the alternative 
IRM model is given by Gordon et al. 5,6  For the  LKB mod-
el, parameter fitting could be done in different ways. For 
example, parameters could be derived from single-fraction 
whole-lung irradiation data. 13  However, the intention of 
this work is not to fit model parameters to any specific clin-
ical dataset, but rather to use clinically realistic values to 
illustrate the problem of extracting dose-response curves 
from DVH data. The selected LQ, IRM and LKB models 
provide a realistic test of analysis techniques’ ability to 
extract P(D) and R(D).   
E. Analytical Techniques 
This section explains how covariance and correlation 
values are calculated between dose metrics VD and RP data 
(G, J or I). Additionally, it explains how one may solve for 
R(D) using covariance equations, or regression methods.  
 
E.1. Covariance / Correlation Analysis 
 
Results of clinical trials are frequently reported in the 
form of correlations between RP and dose metrics such as 
MLD, V20, V30, etc. Practical analysis typically uses a 
discrete set of doses, e.g., Dj = 5, 10, ..., 100 Gy, and corre-
sponding metrics VDj = V5, V10, ... , V100. In the follow-
ing it is assumed that a trial has accrued N patients, produc-
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ing DVHs DVHn(d), with corresponding metrics VDn,j, 
damage values Gn, risk values Jn, and incidence values In, n 
= 1, ..., N. To simplify presentation, the index n is sup-
pressed. Correlations and covariances are understood to be 
evaluated over the DVH set (i.e., index n). From equation 
(2), damage can be approximated as a sum 
 	 ≈ 	∑ 	 	4 ∙ 	4 (8) 
 
where the sum is over j,  Rj ≡  R(Dj) ·  ∆D, and ∆D is the 
dose bin size, here equal to 5 Gy. Using equation (8), 56	, 	 can be approximated 
 56	, 	 		≈ 		∑ 	 56 	, 4	 	 ∙ 		4				 (9) 
 
Note that the function H() and its inverse are assumed 
unknown. However, if  7	 = ln7/1 − 7		  is the logit 
function, then  	 closely approximates a linear function of 
G 
  	 	≈ 		: + 	;	 ∙ 			 ≈ 		: + 	;	 ∙ ∑ 		4 ∙ 	4	 (10) 
 
where κ and λ are unknown constants. Combining (9) 
and (10) gives 
 56	,  		 		≈ 		;	 ∙ 	∑ 	 56 	, 4	 	 ∙ 		4 				 (11) 
 
This work performs all analysis within Matlab®. Correla-
tions and covariances are computed using Matlab’s corr() 
and cov() functions.  
 
E.2. Matrix Solutions 
 
If ̃  is defined to be the column vector of covariances 56 	, 	 , =>  the column vector of covariances  56 	,  		,  ?̃  the column vector of Rj , and M ≡ [Mij]  
the covariance matrix  56 	, 4	,  then equations (9) 
and (11) may be written in matrix form 
 ̃ 		= 		@	?̃ 	+		 AB̃ 			 (12) => 		= 		;	@	?̃ 	+ 		 AC̃ 			 (13) 
 
where  A2̃ 	 and  AC̃ 	 are error vectors that convert the ap-
proximations (9) and (11) to equalities. We focus on equa-
tion (12), but the following comments also apply with adap-
tation to (13). Intuitively, the elements of  AB̃ 	 can be made 
arbitrarily small by using many closely-spaced dose metrics 
VDj in (8). If AB̃ 	  is zero, equation (12) is easily solved:  ?̃ = @D	̃	. If AB̃ 	 is small but non-zero, one can formally 
solve the matrix equation, but a problem arises. If the matrix 
M is close to being degenerate, the problem is referred to as 
ill-posed. In that scenario, small amounts of noise cause the 
formal solution of (12) to diverge widely from the true (ze-
ro-noise) solution. Additionally, small differences in the 
noise cause large variations in the formal solution, making 
the formal solution useless.  
As will be demonstrated below, the present problem — 
extracting P(D) and R(D) from DVH data — is ill-posed. 
Many real-world problems are ill-posed, requiring regulari-
zation. Regularization refers to the strategy of adding a 
penalty term to the problem, which has the effect of reduc-
ing its sensitivity to noise, allowing the solution of the mod-
ified (regularized) problem to closely approximate the solu-
tion of the original zero-noise problem. Here we utilize 
Tikhonov regularization, which solves the matrix problem 
(12) by minimizing  ‖@	?̃ − 	 ̃‖ +	‖Γ	?̃‖, where Γ  is a 
Tikhonov (penalty) matrix. A common choice is Γ	 = 	α	I	, 
where α is a small scalar and I is the identity matrix. This 
choice penalizes the vector norm of  ?̃ , selecting a solution 
that has fewer non-zero elements. A more appropriate 
choice for the present problem is  
 
Γ		 = 		 I 		J
		1			110
−1			111
1		−1⋱1
1						⋱1
				0													−1 M	 (14) 
 
As described in Reichel and Ye 14, this matrix is a finite 
difference approximation to a derivative. It penalizes jag-
gedness in ?̃ , selecting a smooth solution. The Tikhonov 
regularized solutions of equations (12) and (13) are 15  
 ?̃ 	= 		 @N@ +	ΓNΓ	D	@N	̃ (15) ?̃ 	= 		 ;D	@N@ +	ΓNΓ	D	@N	=>	 (16) 
 
Equation (15) determines ?̃  exactly. Equation (16) de-
termines ?̃  up to an unknown multiplier λ.  
 
E.3. Regression Solutions 
 
A generalized linear model (GLM) 16 expresses a de-
pendent variable y in terms of a linear combination of  m  
independent variables x, via a link function  f () 
 O		 = 		 PDQR	 	+ 		A			 (17) 
 
In equation (17), Y is an  n x 1 column vector of observa-
tions of  y, X is an n x m matrix of observations of  x,  w is a 
column vector of weights and  A   represents noise. The 
problem is to extract the weights w given observations Y 
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and X containing some degree of noise. Equation (8) is in 
the form (17), with y ↔ G, x ↔ VDj, w ↔ Rj and identity 
link function. Equation (10) is also in the form (17), with y 
↔ L(J) , x ↔ VDj, w ↔ Rj and identity link function. Final-
ly, RP incidence I may be expressed in the form (17), where 
y ↔ I, x ↔ VDj, w ↔ Rj and  f() is the logit or inverse LKB 
function.  
All of these problems may be solved using regression al-
gorithms designed for GLM problems. This work reports on 
the use of  Matlab’s glmfit() and lassoglm() functions. It 
also uses Mineault’s glmfitqp() function. 17 The Matlab 
functions attempt to extract best-fit weights w by minimiz-
ing the norm of 	A. The glmfitqp() function uses a maximum 
likelihood approach, and allows for a quadratic smoothness 
penalty  ‖Γ	R‖  with  Γ  as in equation (14). 
III. RESULTS 
A. Covariance / Correlation Analysis 
Figure 3 plots  56 	, 4	 and 5?? 	, 4		 to il-
lustrate the strong correlations that exist between dose met-
rics VD
 
within a clinical DVH dataset. Fig. 3a-b plots 5630	, 4		 and 5??30	, 4	  for Dj = 5, 10, ... , 
100 Gy.  The gray lines represent the covariance and corre-
lation (CC) for 10 simulated clinical trials, each consisting 
of 100 DVHs. The central solid blue line is the average. The 
outer dashed blue lines represent the average ± one standard 
deviation. Fig. 3c-d plots mean 56 	, 4		 and mean 5?? 	, 4	  (10 trials x 100 DVHs) for the case where 
simulated DVHs are generated from the full UM DVH set. 
Fig. 3e-f plots mean 56 	, 4		  and mean 5?? 	, 4	  (10 trials x 100 DVHs) for the case where 
simulated DVHs are restricted to the MLD range 15 Gy ≤ 
MLD ≤ 20 Gy.  
Figure 4 plots 56	, 	 , 5??	, 	 , 56	, '	 
and 5??	, '	. Plots of 56	, 	 and 5??	, 	  are 
visually similar to plots of 56	, 	 and 5??	, 	, 
so are not shown. Fig. 4a-d are for the case where simulated 
DVHs are generated from the full UM DVH set. Fig. 4e-g 
are for the case where simulated DVHs are restricted to the 
MLD range 15 Gy ≤ MLD ≤ 20 Gy. All results were ob-
tained by simulating 10 trials x 100 DVHs. The gray lines 
show the results for individual trials. The solid gray and 
blue lines are for the LQ dose-response model. The dotted 
gray and red solid lines are for the IRM dose-response mod-
el.  
Figure 5 plots the percentage of trials in which VD has a 
statistically significant (p < 0.05) correlation with G or I, 
and the percentage of trials in which VD has the most sig-
nificant (smallest p-value) correlation with G or I. These 
results were obtained by simulating 100 trials x 100 DVHs. 
Note that plots of correlations with J are visually similar to 
those for G, so are not shown. Fig. 5a-d are for the case 
where simulated DVHs are generated from the full UM 
DVH set. Fig. 5e-g are for the case where simulated DVHs 
are restricted to the MLD range 15 Gy ≤ MLD ≤ 20 Gy. 
Blue bars are for the LQ dose-response model. Red bars are 
for the IRM dose-response model. 
 
B. Matrix  Solutions 
Figs. 6a-b show solutions of the matrix equation (12) for 
the case where there is zero noise. To generate these results, 
zero-noise profiles  TU	  were defined as follows: 
 TU	 	= 		∑ 				V − 	WXY#  (18) 
 	 is the LQ or IRM profile from Fig. 2b. The LQ 
profile is reproduced as the blue line in Fig. 6a. The IRM 
profile is reproduced as the red line in Fig. 6b. The sum in 
(18) is over the discrete set of doses d = 5, 10, ... , 80 Gy. 
The delta functions ensure that TU	 is non-zero at only 
those doses, causing the approximation in equation (8) to be 
exact, and the noise A2̃ in equation (12) to be zero. Fig. 6 is 
based on 10 trials x 100 DVHs. The gray lines in Figs. 6a-b 
are the solved profiles:  ?̃ = @D	̃	. For all trials, the solu-
tion exactly matches (18)  —  gray lines for the 10 trials 
overlie one another.  
Figs. 6c-d show solutions  ?̃ = @D	̃	  for the case where 
profiles TU	 are still employed, but where 1% uniformly 
distributed noise is artificially added to G. Because the 
covariance matrix M is close to being degenerate, the prob-
lem is ill-posed and that small amount of noise is enough to 
make the solved profiles  ?̃  incorrect. If no noise is added to 
G, but the true profiles R(D) are employed in place of the 
zero-noise profiles TU	, one obtains plots that are very 
similar to Figs. 6c-d. The approximation of the continuous 
integral (2) by the discrete sum in (8) introduces enough 
noise to produce erroneous estimates of R(D).  
Figs. 6e-f show the Tikhonov regularized solutions (15) 
for the case where the true profiles 	 are used to calcu-
late G, no additional noise is added, dose metrics V5, V10, 
... , V100 are included in the covariance matrix, and the 
Tikhonov multiplier α in equation (14) is equal to 0.001. 
The regularized solution does an adequate job of reproduc-
ing the true profiles up to 100 Gy.  
The results in Fig. 6 were obtained by simulating 10 tri-
als x 100 DVHs, using the full DVH dataset, and covari-
ances 56	, 	 (equation(15)). If one uses the restricted 
DVH set with 15 Gy ≤ MLD ≤ 20 Gy, the non-regularized 
solutions in Figs. 6c-d are a little less variable, and the regu-
larized solutions in Figs. 6e-f are clustered a little more 
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tightly around the true profile, but results are otherwise 
similar. If one uses covariances 56	,  		 and solves 
equation (16), results are very similar  —  solutions using 
logit(J) are essentially equivalent.  
 
C. Regression  Solutions 
If regression solutions are generated for G or J vs VD for 
the zero-noise problem (i.e., 	 replaced by TU	), the 
obtained solutions are exact, resembling Figs. 6a-b. In this 
case, Matlab’s glmfit() function is able to find the solutions. 
If the true profiles R(D) are employed, introducing noise 
through the approximation (8),  glmfit()  solutions are un-
stable, as shown in Figs. 7a-b. If Lasso or ElasticNet regu-
larization is attempted using Matlab’s  lassoglm()  function, 
the algorithm fails to converge to a solution, exiting after 
reaching its iteration limit. If Mineault’s glmfitqp() function 
is employed, stable solutions are obtained, as shown in Figs. 
7c-d.  
If Mineault’s algorithm is used to regress  I against VD, 
simulation of 10 trials x 100 DVHs gives the solutions in 
Figs. 7e-f. The extra variability in I (as compared with G or 
J) challenges the algorithm. If Mineault’s algorithm is again 
used to regress  I against VD, simulation of 10 trials x 1000 
DVHs gives the solutions in Figs. 7g-h. Expanding the size 
of the trials from 100 to 1000 DVHs (i.e., patients) gives the 
algorithm more data to work with, ensuring somewhat more 
accurate results. In the case of regression, R(D) estimates 
obtained using a restricted subset of DVHs have noticeably 
more variability than solutions obtained using the full DVH 
set. In the case of the simulations, restricting the regression 
analysis to a subset of DVHs appears to be counter-
productive.  
 
D. Regression Solution of the Original UM Data 
The clinical trial data provided by the University of 
Michigan included DVHs and RP incidence (Fig. 1), but no 
surrogate measurements of damage G, and insufficient data 
to generate reliable estimates of risk J. Fig. 8 shows the 
estimates of R(D) extracted from the UM clinical trial data. 
These estimates were obtained by performing regression of  
I against VD, using the UM incidence data in Fig. 1 (G2+ vs 
G1– cases) and Mineault’s glmfitqp() function.   
IV. DISCUSSION 
A. Correlation Analysis 
Fig. 3d shows that when all DVHs are included in the 
analysis, strong correlations (i.e., correlations ≥ ~0.8) exist 
between all dose metrics V5 – V50. In equations (11) and 
(12) this ensures that many VDi / Rj combinations contrib-
ute strongly to G, making it more challenging to identify the 
impact of any single Rj, or to detect the differences in G 
resulting from different R(D) profiles.  Fig. 3f shows that 
when analysis is restricted to DVHs matching a narrow 
MLD range, correlations 5?? 	, 4		 are more narrow-
ly peaked around  Z = [. This increases the probability of 
detecting the differences in G resulting from different R(D) 
profiles.  Clinical DVH datasets tend to include large num-
bers of cases that have negligible RP risk. For example, 
there are no cases of RP for DVHs having MLD < 15 Gy in 
Fig. 1. Paradoxically, including large numbers of these 
“uninformative” DVHs in correlation analysis tends to blur 
correlation profiles, making it more difficult to establish a 
connection with the underlying dose-response profile.  
This is confirmed by Fig. 4.  In Figs. 4a-d, where results 
have been generated using the full DVH set, the LQ and 
IRM models exhibit similar profiles, making it difficult to 
discriminate the dose-response model based on the correla-
tion profiles. In contrast, in Figs. 4e-f, where results have 
been generated using the restricted DVH set, the LQ and 
IRM models exhibit differently-shaped profiles, making it 
feasible to test the hypothesis that the true dose-response is 
e.g., LQ and not IRM. Non-parametric tests such as Kolmo-
gorov-Smirnov could possibly be adapted for this purpose. 
However, discrimination is only possible using the covari-
ance or correlation of G (or J) with VD. Correlations of I 
with VD (Fig. 4h) are very small, and dominated by inter-
trial noise, rendering hypothesis testing impossible.  
When testing for statistically significant correlations (p < 
0.05) of VD with G, J or I, one is testing for non-zero corre-
lations, without any regard to the size of the correlations. If 
one accepts a local injury model (equation (2)), all dose 
metrics VD contribute to G at some level. Therefore, it 
would not be surprising to find that a wide range of VD 
exhibit non-zero correlation. Guckenberger, for example, 
reports significant correlations for V2.5 – V50. 18  In the 
case of incidence data, Fig. 5c shows that most VD are 
significantly correlated with I in fewer than 100% of trials. 
This implies that there is some trial-to-trial variability in the 
set of apparently correlated VD. This is reinforced by Fig. 
5d, which shows that any VD can register the most signifi-
cant correlation in some subset of trials. It follows that no 
significance can necessarily be read into the fact that certain 
VD, e.g., V5 or V13, are significantly correlated with RP in 
some trials, but not in others. This occurs simply as a result 
of variations in the DVH set, and does not necessarily re-
veal anything useful about the patient cohort or the underly-
ing biological dose-response relationship.  
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B. Matrix & Regression Solutions 
Figures 6 and 7 show the value of using a smoothness 
penalty when estimating R(D), rather than alternative types 
of regularization (Ridge, Lasso, ElasticNet) that penalize 
the number of non-zero elements in ?̃  , or the L1 or L2 
magnitude of  ?̃. Alternative regularization methods apply 
the wrong type of penalty for this problem, leading to inva-
lid results.  
This work considers the ideal situation where RP is de-
termined solely by the DVH and an (unspecified)  sigmoid 
risk function. Real-world data will reflect other non-dose-
related factors, such as the effect of comorbidities, perfor-
mance status, genetic markers, chemotherapy, etc. Extrac-
tion of dose-response from real-world data may therefore be 
more challenging. This work provides optimism that dose-
response functions can be extracted from clinical damage or 
risk data (G or J). However, incidence data (I) still appears 
too challenging,, unless trials enroll substantially larger 
numbers of patients than is presently the case, or DVH plus 
complication data from multiple trials is pooled.  
 
C. Dose-Response Determination 
The general problem addressed in this work is how to de-
termine the full DVH dependence of radiation-induced 
tissue injury, from clinical DVHs plus measures of tissue 
damage (G, J or I). At the present time, data regarding tissue 
damage (i.e., RT complications) is most commonly supplied 
in the form of grading data. In the case of radiation pneu-
monitis, a physician classifies each patient as grade 0, 1, 2, 
... based on symptoms and imaging. Grading is performed 
according to SWOG, CTCAE or other scheme. 19  Grading 
data is frequently reduced to binary incidence I by setting a 
severity threshold  —  in this work we consider G2+ versus 
G1–  RP.  
Even with strict controls, physician grading of RT com-
plications is inevitably subjective. For example, the chal-
lenges associated with the grading of radiation pneumonitis 
are discussed in the Quantec paper. 1  The results of this 
work effectively ignore subjectivity in RP grading  —  sim-
ulated incidence data is generated from the NTCP model, 
assuming the underlying damage and risk values can be 
calculated exactly. The results given here show that, even 
without the subjectivity associated with different physi-
cians, different institutions, uneven follow-up, and uneven 
imaging capabilities, the variability inherent in incidence (or 
grading) data makes it extremely challenging to extract 
DVH dependence. As long as clinical trials continue to 
provide results in the form of simple ordinal grading data, it 
seems doubtful that further quantitative insight will be pro-
vided into radiation dose-response.  
This work shows that, if quantitative volumetric 
measures of tissue damage are available (G or J), it is feasi-
ble to determine DVH dependence using available algo-
rithms. Fortunately, quantitative volumetric measures of 
tissue damage are becoming technically feasible, courtesy 
of functional magnetic resonance imaging (fMRI) , MR 
spectroscopy (MRS), diffusion weighted imaging (DWI),  
diffusion tensor  imaging (DTI), arterial spin labelling 
(ASL), and other advanced imaging techniques. 20 The clin-
ical utility of these techniques remains to be determined. 
However, each produces one or more candidate surrogate 
measurement of some aspect of tissue damage, to which the 
techniques of this work can potentially be applied.  
The techniques developed here utilize integral, as op-
posed to regional, measures of tissue injury. It is reasonable 
to ask whether one could bypass  integral measures, and use 
the above imaging techniques to directly measure regional 
tissue injury. In that case, imaging would directly measure 
the dose response function P(D). As imaging techniques 
continue to advance, this may become possible. However, 
direct measurement of regional damage can rely on deform-
able image registration (DIR), which is subject to its own 
uncertainties. A number of studies have attempted regional 
measurements, and found them to be challenging. 21,22 For 
lung, Liao notes that  “measurements of regional lung func-
tion are difficult and pulmonary function tests most often 
assess total lung function”. 23 
Additionally,  it remains conceivable that the injury 
caused by radiation dose deposition in one voxel may actu-
ally manifest at a different location in the organ. In the case 
of lung, out-of-field injury has been clinically observed. 24,25 
The mechanisms of in vivo tissue damage involve organ-
level and systemic immune response, and could  involve 
bystander signaling. 26, 27 Until the various mechanisms 
involved in radiation induced injury are better understood, 
these factors may complicate accurate regional measure-
ments. Integral injury measurements are likely to be robust 
to the uncertainties associated with regional measurements, 
and therefore could provide a more reliable method of de-
termining DVH dependence.  
The principal innovations of this work are to show that 
the problem of determining DVH dependence from DVHs 
plus injury data is ill-posed, and that smoothness regulariza-
tion can counter this problem, enabling reliable solution. 
The ill-posedness is due to the strong correlations between 
dose metrics VD within clinical DVH sets. This work 
demonstrates two forms of smoothness regularization — 
Tikhonov regularization of a matrix solution, and a smooth-
ness penalty term added to a regression solution. However, 
other forms are possible. For example, functional principal 
components analysis (FPCA) can achieve the same end, by 
expressing solutions in terms of smooth orthonormal basis 
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functions. 28 The factor enabling DVH dependence to be 
successfully extracted is that some form of smoothness 
regularization be employed.   
V. CONCLUSIONS 
This work is predicated on a local injury model of nor-
mal lung, in which radiation-induced damage is the integral 
of the cumulative DVH with a dose-response function R(D), 
RP risk is a sigmoid function of integral damage, and inci-
dence is related to risk via the Bernoulli distribution. A 
homogeneous patient cohort is assumed, allowing all non-
dose-related determinants of RP to be ignored. Using simu-
lated DVH plus RP data, the ability of correlation and re-
gression analysis to extract the dose-response function is 
examined.  
In problems of this type, correlation analysis is often 
used to identify the subset of candidate predictor variables 
that are significantly correlated with the outcome, and 
should therefore be included in a predictive model. This 
approach makes little sense for the case where lung damage 
depends on all variables VD, courtesy of the integral with 
R(D). Correlation analysis therefore has limited value. It is 
demonstrated that the subset of VD that are significantly 
correlated with RP varies randomly from trial to trial. This 
suggests that no significance can necessarily be attached to 
the fact that certain VD, e.g., V5 or V13, are significantly 
correlated with RP in some trials, but not in others. This 
occurs simply as a result of random variations in the DVH 
set, and does not necessarily reveal anything useful about 
the patient cohort or the underlying biological dose-
response relationship.  
This work was not successful in extracting R(D) from in-
cidence data (I), due to its higher level of statistical variabil-
ity. However, regression or matrix analysis has the potential 
to extract R(D) from damage or risk data, provided appro-
priate smoothness regularization is employed. To the au-
thors’ knowledge, smoothness regularization has not previ-
ously been applied to this problem, so represents a novel 
approach. In particular, this work shows that dose-response 
functions can be successfully extracted from  measurements 
of integral (as opposed to regional) lung damage G, suggest-
ing value in re-visiting available measurements of ventila-
tion, perfusion and radiographic damage. The techniques 
developed here can potentially be used to extract the dose-
response functions of different tissues from multiple types 
of quantitative volumetric imaging data.  
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Figure 1:  Plot of mean lung dose (MLD) versus DVH number for the University of Michigan dataset. Actual radiation 
pneumonitis (RP) incidence, derived from the clinical trial, is indicated by symbol. Pink solid triangles are grade 3 DVHs. 
Red solid circles are grade 2 DVHs. Blue hollow diamonds are grade 1 DVHs. Gray hollow squares are grade 0 DVHs. Note 
that these toxicity gradings are ignored in the simulated trials. In the simulations, RP incidence is generated using equations 
(2-4). The gray band indicates the subset of DVHs (i.e., those having 15 Gy ≤ MLD ≤ 20 Gy) which was used for some sim-
ulations.  
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Figure 2:  (a) Dose-damage profiles P(D) corresponding to the linear quadratic (LQ) model (blue solid line) and Induced 
Repair Model (IRM) (red dashed line). (b) Rate profiles R(D) corresponding to the LQ and IRM models. The rate profile is 
the derivative of the damage profile: R(D) = P′(D).  
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Figure 3: Plots of covariance and correlation (CC) between dose metrics VD. (a-b) CC between V30 and VD, where D = 5, 
10, ... , 100 Gy (x-axis). The gray lines are the CC obtained for 10 simulated clinical trials, each containing 100 DVHs. The 
central solid blue line is the average. The outer dashed blue lines represent the average ± one standard deviation. (c-d) Aver-
age CC between VDi and VDj, where simulated DVHs are generated from the full UM DVH set. (c-d) Average CC between 
VDi and VDj, where simulated DVHs are restricted to the MLD range 15 Gy ≤ MLD ≤ 20 Gy. 
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Figure 4: Plots of covariance and correlation (CC) between G, I and dose metrics VD. Gray lines are for individual trials. 
Blue and red lines are averages over the trials. The solid gray and blue lines are for the LQ dose-response model. The dotted 
gray and red solid lines are for the IRM model. (a-d)  CC for the case where simulated DVHs are generated from the full 
UM DVH set. (e-h) CC for the case where simulated DVHs are restricted to the MLD range 15 Gy ≤ MLD ≤ 20 Gy. 
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Figure 5: (a,c,e,g)  Plots of the percentage of trials in which VD has a statistically significant (p < 0.05) correlation with G 
or I. (b,d,f,h) Plots of the percentage of trials in which VD has the most significant (smallest p-value) correlation with G or I. 
Panels a-d are for the case where simulated DVHs are generated from the full UM DVH set (labelled “full”). Panels e-h are 
for the case where simulated DVHs are restricted to the MLD range 15 Gy ≤ MLD ≤ 20 Gy (labelled “sub”). Blue bars are 
for the LQ dose-response model. Red bars are for the IRM dose-response model.  
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
full,G full,G 
full,I full,I 
sub,G sub,G 
sub,I sub,I 
 15 
Outcome Modeling Using Clinical DVH Data 
Figure 6:  Estimates of R(D) obtained using matrix methods. Panels a,c,e show results for the LQ profile (blue line). Panels 
b,d,f show results for the IRM profile (red line). Gray lines are the 10 estimates of  R(D) obtained from 10 trials x 100 DVHs. 
Results are for the full DVH dataset. Results for the restricted DVH dataset having 15 Gy ≤ MLD ≤ 20 Gy are visually simi-
lar. (a-b)  Solutions  ?̃ = @D	̃	  for the case where there is zero noise (i.e., R(D) is replaced by RZN(D) in the damage calcu-
lations). (c-d)  Solutions  ?̃ = @D	̃	  for the case where small amounts of noise are added to G. (e-f)  Solutions of the 
Tikhonov regularized equation (15).  
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Figure 7: Regression solutions for simulated data. (a-b)  G vs VD using Matlab’s glmfit() function. (c-d)  G vs VD using 
Mineault’s glmfitqp() function. (e-f)  I vs VD using Mineault’s glmfitqp() function, 10 trials x 100 DVHs. (g-h)  I vs VD 
using Mineault’s glmfitqp() function, 10 trials x 1000 DVHs. 
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Figure 8:  Regression solutions for University of Michigan clinical trial data.  (a) R(D) extracted using full DVH dataset 
(gray line), compared with LQ model (blue solid line) and IRM model (red line). (b) R(D) extracted using restricted DVH 
dataset having 15 Gy ≤ MLD ≤ 20 Gy.  
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